<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-V5C321IC</identifier><date>2022</date><creator>Avsec, Damjan</creator><creator>Mlinarič-Raščan, Irena</creator><creator>Podgornik, Helena</creator><creator>Škerget, Matevž</creator><relation>documents/doc/V/URN_NBN_SI_doc-V5C321IC_001.pdf</relation><relation>documents/doc/V/URN_NBN_SI_doc-V5C321IC_001.txt</relation><format format_type="issue">5</format><format format_type="volume">73</format><format format_type="type">article</format><format format_type="extent">str. 410-417</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">132626435</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-V5C321IC</identifier><language>slv</language><publisher publisher_location="Ljubljana">Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">akalabrutinib</subject><subject language_type_id="slv">BTK</subject><subject language_type_id="slv">ibrutinib</subject><subject language_type_id="slv">Imunoterapija</subject><subject language_type_id="slv">Kronična limfocitna levkemija</subject><title>Tarčno zdravljenje kronične limfocitne levkemije z zaviralci Brutonove tirozin kinaze</title><title>Targeting Bruton’s tyrosine kinase in chronic lymphocytic leukemia</title></Record>